



May 20, 2025

**amfAR**

Thank you for joining, the webinar will start soon.

**Dr. Andrea Gramatica**  
Vice President and Director, Research

**Kent Cozad**  
Director, Grants Administration and Compliance

## Presentation Outline

1. Introduction: Background and Purpose
2. Award Amount and Duration
3. Application Process
4. Q&A

## Introduction: Background and Purpose

amfAR's research initiatives are aimed at finding a cure for HIV that will be useful to the 40M people living with HIV (PLWH).

The urgency of our goal demands that we direct our funding to studies that uncover vital knowledge directly applicable to **clinical** or **pre-clinical cure efforts**.

amfAR's Target Grants should focus on pushing the boundaries of biomedical research to achieve complete **HIV viral eradication** or **sustained viral remission**.

## Introduction: Background and Purpose

### Pragmatic and scalable solutions

Priority will be given to clinical or pre-clinical applications studying pragmatic and scalable interventions that can be implemented globally, including in the communities most affected by the epidemic.

### Only in vivo or ex vivo applications

The proposed research must be conducted either in vivo (in PLWH, non-human primates, or humanized mice), or ex vivo (in cells isolated from PLWH or infected animals). Interventions tested exclusively in cell lines or in primary cells from HIV-negative individuals will not be considered responsive to this RFP.

### No descriptive studies

Submissions that propose only describing the reservoir (i.e., without pre-clinical or clinical interventions) will not be forwarded for review, unless they provide new and critical insights that have the clear potential to meaningfully accelerate HIV cure strategies.

## Introduction: Background and Purpose

The Target Grants RFP is focused exclusively on **biomedical research** directly related to HIV cure.

The following types of research are not eligible:

- Epidemiological studies
- Behavioral or social science research
- Health services research
- Policy or implementation science studies
- Basic science projects using only cell lines or samples from HIV-negative individuals
- Studies focused on HIV prevention or medical treatment

## Award Amount and Duration

### Previous year

**Type 1:** Up to \$480,000 (including up to 20% indirect costs).  
Up to **two years** duration.

**Type 2:** Up to \$120,000 (including up to 20% indirect costs).  
Up to **one-year** duration.

### Current year

**Type 1:** Up to \$480,000 (including up to 20% indirect costs).  
Up to **two years** duration.


---

For example:

1. If you budget \$400K for direct costs (with no subawards), you can apply an indirect cost rate of 20%, for \$80K in indirect costs.
2. If your institution accepts a lower indirect cost rate, you can budget more for direct costs: e.g., if your institution accepts 10% indirect costs, you can budget up to \$440K for direct costs.

amfAR **doesn't allow indirect cost rates higher than 20%.**

## Application Process: Overview



## Application Process: Synopsis

### amfAR

#### TARGET GRANT SYNOPSIS

Completed synopsis should be submitted to [grants@amfar.org](mailto:grants@amfar.org)

In the email's subject line, please write: Principal Investigator's LAST NAME, FIRST NAME - TARGET GRANT

#### Principal Investigator

Name:  Highest Degree:  Institution:

#### Co-Principal Investigator (optional)

Name:  Highest Degree:  Institution:

#### Collaborator(s) (optional)

Name:  Highest Degree:  Institution:

Name:  Highest Degree:  Institution:

Name:  Highest Degree:  Institution:

#### Project title

#### Which model system(s) will be used in this project?

- ☐ In vitro, cell line  
☐ In vitro, primary cells (e.g., cells isolated from HIV negative donors and infected/treated in vitro)  
☐ In vivo, cells or tissues (e.g., cells or tissues directly isolated from PLWH)  
☐ In vivo, animal model  
☐ In vivo, human participants

Is there existing peer-reviewed data supporting the rationale of this project? Please provide links to publications.

In vitro safety/efficacy:


In vivo safety/efficacy:

In vivo safety/efficacy:

Plan narrative (250 words or less)


If successful, what comes next? (250 words or less)

## Application Process: Research Plan



## Application Process: Research Timeline

	Year 1												Year 2											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Aim 1																								
Aim 2																								
Aim 3																								
Interim Report due at the end of Year 1													Final Report due at the end of Year 2											



**amfAR**

**Questions?**  
Email: [grants@amfar.org](mailto:grants@amfar.org)